NuvoLase Inc. is a privately held Delaware corporation formed in August 2011 and located in Northern California. In September of 2011 NuvoLase Inc. acquired certain rights, assets and intellectual properties associated with the PinPointe FootLaser. NuvoLase is actively engaged in future product development based on the unmet needs of clinicians and patients worldwide.
PinPointe FootLaser, NuvoLase’s first and flagship product is the first light-based device to receive FDA clearance specific to the treatment of Onychomycosis (nail fungus), and is recognized by industry leaders as the gold standard product and alternative treatment for those patients suffering from Onychomycosis. Regulatory clearances for the PinPointe FootLaser include FDA clearances, CE Mark, TGA and Health Canada with other clearances pending.
All NuvoLase products provide superior clinical performance and the result of solid research, sound science and clinical studies.